Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Operating Expenses
Samsung Biologics Co Ltd
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Operating Expenses
-₩689.1B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Operating Expenses
-₩17B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Operating Expenses
-₩37.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Operating Expenses
-₩78.6B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Operating Expenses
-₩10B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Operating Expenses
-₩98.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-30%
|
See Also
What is Samsung Biologics Co Ltd's Operating Expenses?
Operating Expenses
-689.1B
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Operating Expenses amounts to -689.1B KRW.
What is Samsung Biologics Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-50%
Over the last year, the Operating Expenses growth was -42%. The average annual Operating Expenses growth rates for Samsung Biologics Co Ltd have been -77% over the past three years , -50% over the past five years .